VKTX
25.17-2.20 -8.04%Past year
Loading chart…
Loading financials…
Company snapshot
- Ticker
- VKTX
- Exchange
- NCM
- Sector
- Healthcare
- Industry
- Biotechnology
- Market cap
- $3.39B
- Employees
- 65
- Currency
- USD
- Website
- https://www.vikingtherapeutics.com
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company…
Latest coverage
- 3 Absurdly Cheap Stocks to Buy Before the End of 2026
October 13, 2026
Related Other stocks
UnitedHealth Group IncorporatedUNH
J.B. Hunt Transport Services, Inc.JBHT
Zillow Group, Inc.ZG
Opendoor Technologies Inc.OPEN